TinyGemsBreaks Archive - Page 82 of 128

TuesdayFeb 21, 2023 12:39 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Findings from Hypertension Study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, is reporting additional findings from its human clinical study HYPER-H21-4; the study is designed to demonstrate a potentially novel mechanism of action of LEXX’s patented DehydraTECH-processed cannabidiol ("CBD") capsule formulation in the treatment of blood pressure ("BP"). According to the announcement, Lexaria believes that those findings, which were published in the peer-reviewed “Biomedicine and Pharmacotherapy" journal, could support DehydraTECH-CBD qualification within existing Food and Drug Administration (“FDA”) guidelines. Previous results of the study indicated that primary efficacy and safety objectives were successfully achieved, including hypertensive patients seeing resting blood pressure…

TuesdayFeb 21, 2023 10:55 am

TinyGemsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Builds on Growing Success with Sales of New K1 Call Boxes

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots and blue light emergency communication systems, sees continued growth through sales of 11 K1 Call Boxes to Larimer County, Colorado. The transaction was completed through KSCP resale partner Stream Speed Technologies (“SST”). Knightscope’s smallest emergency call box system, the K1 Call Box, offers one-touch connection with a ruggedized housing and simple interface. The call box offers a completely wireless solution for emergency phone calls and can also work with existing nearby wiring nearby. In addition, the system includes additional options that allow people who are deaf, hard of hearing or…

TuesdayFeb 21, 2023 10:38 am

TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q2 2023 Financial, Corporate Report

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, is reporting on its second quarter of fiscal year 2023, the period that ended Dec. 31, 2022. Highlights of the report include the company closing the calendar year with nearly $11.5 million in cash and the completion of enrollment in the company’s phase 2 clinical trial in epidermolysis bullosa (“EB”). The report also noted that the company has seen advancement in its research using rare cannabinoids in the treatment of glaucoma and neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s. “This…

FridayFeb 17, 2023 12:55 pm

TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD Demonstrates ~1,900% Better Permeability Through Skin

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced its 28th granted patent worldwide and the first granted patent from its sixth patent family, titled Transdermal And/or Dermal Delivery of Lipophilic Active Agents. “The Canadian patent #3,093,414 is for improved compositions and methods for transdermal and dermal delivery of cannabinoids, including cannabidiol (‘CBD’) and tetrahydrocannabinol (‘THC’), all established on the company’s patented DehydraTECH technology,” a recent article reads. “In Lexaria’s 2018 study, DehydraTECH-CBD demonstrated almost a 1,900% increase in CBD permeability through human skin compared to a control formulation that was devoid of any commercial…

ThursdayFeb 16, 2023 11:30 am

TinyGemsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Launches Major Fr8TMS Update

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”) is a technology company whose custom-developed Fr8App is an industry-leading freight-matching platform powered by AI and machine-learning and offers a real-time portal for B2B cross-border shipping and domestic shipping within the USMCA region. The company today announced the launch of a major update for its transportation management system (“Fr8TMS”). The new update is designed to transform the commercial trucking industry by introducing logistics and transportation technology to move freight within the USMCA region, with a focus on cross-border shipping. “We are excited to introduce this new update to the Fr8TMS, which will revolutionize the commercial…

WednesdayFeb 15, 2023 12:04 pm

TinyGemsBreaks – Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) Completes Strategic Sale of Alta Mesa Project

Energy Fuels (NYSE American: UUUU) (TSX: EFR) today announced its completion of the sale of three wholly owned subsidiaries that together hold its Alta Mesa ISR Project to enCore Energy Corp. “Energy Fuels’ sale of the Alta Mesa project for $120 million of total consideration is highly strategic for a variety of reasons,” said UUUU CEO and President Mark S. Chalmers. “When combined with our already strong balance sheet, the proceeds from this sale are expected to fully fund our current uranium, vanadium and rare earth business plans through approximately 2024 without the dilution to shareholders one might normally expect,…

WednesdayFeb 15, 2023 11:14 am

TinyGemsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Releases Q1 2023 Fiscal, Business Report

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, is reporting on its fiscal first quarter for the period ending Dec. 31, 2022. Highlights of the report include the following: acquiring the assets of Electric Last Mile Solutions (“ELMS”) in a $105 million acquisition move; $100 million in cash being available for operations and investment at the end of Q1 2023; 31, 2022; securing the rights for exclusive sales, distribution and branding for the new compact electric vehicle, the Mullen-GO (formerly I-GO), and initial delivery of the vehicle to the distribution agent; receiving a $200 million purchase order from…

TuesdayFeb 14, 2023 12:52 pm

TinyGemsBreaks – Cepton Inc. (NASDAQ: CPTN) Schedules Release of Q4 and FY 2022 Financial Results, Earnings Call

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, today announced that it will provide a business update and release its financial results for the fourth quarter and full year 2022 following the close of the market on Tuesday, March 14, 2023. Cepton will host a conference call and webcast at 2:30 p.m. PT (5:30 p.m. ET) that same day. Interested parties may join the call by dialing 1-877-300-8521 (toll-free) or 1-412-317-6026 (international) and visiting Cepton’s Investor Relations page to access the live webcast. A telephonic replay will be available approximately two hours after the live…

TuesdayFeb 14, 2023 11:51 am

TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX) Forms US-Based Subsidiary with Focus to Expand Innovation Platforms

Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced the formation of a U.S.-based wholly owned subsidiary, Pearsanta Inc. The move intends to accelerate the expansion of Aditxt’s second program, AditxtScore(TM), through future strategic revenue and growth-oriented transactions. According to the update, Anthony Voorhies, currently the head of the AditxtScore(TM) division, will serve as president of Pearsanta. Voorhies has over 20 years of clinical diagnostics and healthtech industry experience and, under his leadership, the AditxtScore(TM) division has successfully grown from inception to commercialization and revenues in just…

TuesdayFeb 14, 2023 11:28 am

TinyGemsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q3 Financial Report, Corporate Highlights

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), is reporting on its third quarter performance as well as recent business highlights; the report is for the period ended Dec. 31, 2022. In the report, the company noted that it had received approval from an independent ethics committee in the Netherlands to begin the first-in-human dosing of its CYB004 through a protocol amendment to its ongoing phase 1 CYB004-E trial; CYB004 is the company’s proprietary deuterated N,N-dimethyltryptamine (“DMT”) molecule. The company is also making progress on its phase 1/2a clinical trial evaluating CYB003 for the potential treatment…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

TinyGemsBreaks